Biopharma industry veteran to lead company's development of solid tumor cell therapies engineered with immune cells from blood instead of surgically removed cancer tissue

生物制药行业退伍军人领导公司开发实体肿瘤细胞疗法，该疗法采用血液中的免疫细胞而不是手术切除的癌组织

SAN FRANCISCO, Nov. 1, 2023 /PRNewswire/ -- cTRL Therapeutics, a biotechnology company harnessing circulating tumor-reactive lymphocytes (cTRLs) in the blood to broaden the power and reach of solid tumor cell therapy to more patients, today announced the appointment of Derrell D. Porter, M.D., as Chief Executive Officer.

旧金山，2023年11月1日/PRNewswire/-cTRL Therapeutics，一家利用血液中循环肿瘤反应性淋巴细胞（cTRLs）的生物技术公司，将实体肿瘤细胞治疗的力量和范围扩大到更多患者，今天宣布任命Derrell D.Porter，医学博士，首席执行官。

Dr. Porter has over 20 years of biopharmaceutical leadership experience, bringing deep interdisciplinary expertise in the development and commercialization of innovative therapeutics in oncology and cell and gene therapy..

波特博士拥有20多年的生物制药领导经验，在肿瘤学，细胞和基因治疗创新疗法的开发和商业化方面拥有丰富的跨学科专业知识。。

'I'm excited to join cTRL at this pivotal moment of discovery for cell therapies targeted to solid tumors, which make up 90% of adult cancers,' said Derrell Porter, M.D., Chief Executive Officer of cTRL Therapeutics. 'The biggest challenge to making this approach viable has long been the need for an immune cell that can effectively infiltrate the challenging tumor environment, which typically requires cells harvested from the patient's own surgically removed cancer tissue.

cTRL Therapeutics首席执行官Derrell Porter博士说：“我很高兴在这个发现针对实体瘤的细胞疗法的关键时刻加入cTRL，实体瘤占成人癌症的90%使这种方法可行的最大挑战一直是需要能够有效渗透具有挑战性的肿瘤环境的免疫细胞，这通常需要从患者自身手术切除的癌组织中收获细胞。

cTRL has identified this rare and sought-after cell type and also devised a novel platform to efficiently isolate it from blood with speed, specificity, and purity – unlocking the groundbreaking ability to create solid tumor cell therapy from a single blood draw. I look forward to working with the team to advance our technology into the clinic.' .

cTRL已经确定了这种罕见且广受欢迎的细胞类型，并且还设计了一种新型平台，以快速，特异性和纯度有效地将其与血液分离-释放出通过单次抽血创建实体肿瘤细胞疗法的开创性能力。我期待与团队合作，将我们的技术推向诊所 .

'Derrell's experience includes a rare mix of business acumen, clinical development expertise, deep knowledge of the oncology space, and a passion for leading innovation in new treatment modalities that can benefit patients,' said Shana Kelley, Ph.D., Founder and Chief Technology Officer of cTRL Therapeutics.

“Derrell的经验包括罕见的商业敏锐度，临床开发专业知识，对肿瘤学领域的深入了解，以及对能够使患者受益的新治疗方式的领先创新的热情，”Shana Kelley博士，创始人兼首席技术官cTRL Therapeutics。

'We have been searching for the right fit to lead cTRL during this exciting phase, and we believe Derrell's leadership and experience will be extremely valuable in driving the strategy forward as we advance cTRL therapeutics to bridge the gaps in solid tumor cell therapy, another frontier of cancer medicine that represents a potential turning point in the trajectory of human health..

“我们一直在寻找在这个激动人心的阶段领导cTRL的合适人选，我们相信Derrell的领导和经验对于推动该战略的发展将非常有价值，因为我们推进cTRL疗法以弥合实体肿瘤细胞疗法的差距，另一个癌症医学的前沿，代表了人类健康轨迹的潜在转折点。。

Dr. Porter has held leadership roles in several notable biopharma companies. Most recently, he served as founder and CEO of Cellevolve Bio, a biotech company partnering with innovators to bring cell therapies through late-stage development and commercialization with a focus on neglected diseases. He is currently on the boards of Passage Bio, Acumen Pharma, and Portal Innovations.

波特博士在几家着名的生物制药公司担任领导角色。最近，他担任Cellevolve Bio的创始人兼首席执行官，Cellevolve Bio是一家生物技术公司，与创新者合作，将细胞疗法带入后期开发和商业化，重点关注被忽视的疾病。他目前是Passage Bio，Acumen Pharma和Portal Innovations的董事会成员。

Previous to this role, Dr. Porter served as Head of Commercial at Atara Bio, an allogeneic T-cell immunotherapy company and prior to Atara, he held several global roles of increasing responsibility at Gilead Sciences, AbbVie and Amgen. He started his career at McKinsey & Company, helping lead West Coast engagements in the health care practice.

在此之前，Porter博士曾担任同种异体T细胞免疫治疗公司Atara Bio的商业负责人，在Atara之前，他在Gilead Sciences，AbbVie和Amgen担任着越来越重要的全球角色。他在麦肯锡公司（McKinsey＆Company）开始了职业生涯，帮助领导西海岸的医疗保健活动。

He earned his M.D. from the University of Pennsylvania's Perelman School of Medicine, where he was a Gamble Scholar, an M.B.A. in Health Care Management from The Wharton School, and a B.S. in Neuroscience from the University of CA, Los Angeles. .

他从宾夕法尼亚大学佩雷尔曼医学院获得博士学位，在那里他是赌博学者，沃顿学院获得医疗保健管理硕士学位，洛杉矶加州大学获得神经科学学士学位。 .

About cTRL Therapeutics

关于cTRL Therapeutics

cTRL Therapeutics is a biotechnology company harnessing circulating tumor-reactive lymphocytes (cTRLs) in the blood to broaden the power and reach of solid tumor cell therapy to more patients. Through a novel, proprietary platform that can isolate this previously elusive but powerful cancer-fighting cell from blood, we are pioneering the first cell therapies to reach solid tumors without the need for surgically removed cancer tissue.

cTRL Therapeutics是一家生物技术公司，利用血液中的循环肿瘤反应性淋巴细胞（cTRL），将实体肿瘤细胞治疗的力量和范围扩大到更多患者。通过一个新颖的专有平台，可以从血液中分离出这种以前难以捉摸但功能强大的抗癌细胞，我们正在开创第一个达到实体瘤的细胞疗法，而无需手术切除癌组织。

With broad applicability across numerous solid tumors, cTRL therapeutics hold the potential to address the longstanding challenges and complexities of solid tumor cell therapy development, manufacturing and administration. cTRL is founded and led by an exceptional team of industry and immunotherapy experts with deep knowledge of the adaptive immune system, immuno-oncology, biomedical engineering, and cell therapy research and development.

由于cTRL疗法在众多实体瘤中具有广泛的适用性，因此有可能解决实体瘤细胞疗法开发，制造和管理的长期挑战和复杂性。cTRL由卓越的行业和免疫治疗专家团队创立并领导，他们对适应性免疫系统，免疫肿瘤学，生物医学工程和细胞疗法研究与开发有着深入的了解。

For more information, visit www.ctrl-therapeutics.com..

欲了解更多信息，请访问www.ctrl-therapeutics.com。。

SOURCE cTRL Therapeutics

源cTRL治疗